<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/7005">
    <dcterms:title><![CDATA[<strong>Unveiling novel pharmacophores and hit compounds for the development of anti-virals to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SARS-CoV-2]]></dcterms:subject>
    <dcterms:subject><![CDATA[COVID-19]]></dcterms:subject>
    <dcterms:subject><![CDATA[INHIBIDOR DE PROTEASAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD ANTIVIRAL]]></dcterms:subject>
    <dcterms:subject><![CDATA[CETONAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BORO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2025]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The respiratory infection COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2), which continues to spread worldwide causing more than a million deaths yearly. Despite the rapid development of vaccines for prevention, a critical need remains for therapeutic agents to combat the established infection. With this goal in mind, we conducted a target- (SARS-CoV-2 chemotrypsin-like protease, MPro) and phenotypic-based screening of a subset of compounds from our in-house chemo-library. The selected compounds have been previously studied in different diseases’ models. About 45 % of the analyzed compounds displayed inhibitory activity against MPro in the low μM range. Additionally, 3 out of 26 tested compounds (11 %) against SARS-CoV-2 displayed true anti-viral activity and (SI &gt; 2). One of them belongs to the chloroquine-heterocycle chemotype, which was previously reported to hold anti-SARS-CoV-2. The remaining two novel hits belong to the polyhedral‑boron system, metallacarborane and dicarba-closo-dodecaborane chemotypes, which have not been previously reported for this anti-viral activity. In addition to targeting MPro, the chloroquine- and the metallacarborane-derivative, but not the dicarba-closo-dodecaborane, also inhibited the papain-like protease of SARS-CoV-2.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Dávila, Belén</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fló, Martin</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ruatta, Santiago</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Lorenzelli, Franca</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Medeiros Pereyra, Andrea Lourdes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?bc7201c0b5fc56fd836dee4c0d21c287"><strong>Bastidas, Jonathan</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?8932d1b3607fa1afc1c98051379a1980243e9743edfb051c5140458c51791c67d843063ff0ef0b72b9fd6902f6db3eb11e482de7c45e206fcc9fbf2cf44167ec"><strong>Rodríguez, Gonzalo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?9a759f82c760db6892e06ff7c328292f8dca37993528fd8412c2d8d01f7d6d835c3a3081b275edfb3dee2d5c67ed2287353c0c4731575df70998cca81fc384de"><strong>Aguilera, Elena</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>García, María Fernanda</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?abf1f721e3c6c780fdd901e279150859"><strong>Romero, Angel H.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Park, Soonju</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Heo, Jinyeong</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Lee, Honggun</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Jeon, Yeonguk</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Park, Kyuho Paul</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Shum, David</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?703719349e39a99eec152464e8f08cd9f9f9fb2286d6f029200c1c7564ce5a7999708965c91b1824d25369d381afc497aa17eb07cce0d5f2e99cf322b898407f"><strong>López González, Gloria Virginia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?6c900b39f34fd66d595492c30a2cc2232ee9d8610818b5103f774621a54c6bcef9e24003af50ea16ea0b0818ef8096c2a6423a8c54211de8c5c5b3fa15dfc1b0"><strong>Couto, Marcos</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?0226bca4791a36d4b242f38bf75c9651c69d5faf378ce4c90bb15c7409699076cceac7f849be1af4c9cb868a8f752a352b5e959051b538d3361fed0ae3365985"><strong>Cerecetto, Hugo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?d2d10cfa54966517805b1a341fd0bf848459a42edc38be9fb9a47c88059d60c10903a61e095bb7923af761074fca9ed68d0986be2008776e6aa5c43dd7468e2a"><strong>Comini, Marcelo A.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Bioorganic Chemistry, v. 163, 2025. -- e108724]]></dcterms:source>
    <dcterms:publisher><![CDATA[elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2025]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Información sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislación uruguaya protege el derecho</strong> de autor sobre toda creación literaria, científica o artística, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeción a lo establecido por el derecho común y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptación de las siguientes condiciones de uso: Este documento es únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilización o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[10 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Inglés]]></dcterms:language>
    <dcterms:type><![CDATA[Artículo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1002/vms3.70205]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
